Deregulated expression of interferon regulatory factor-1 in oncogene-transformed mouse fibroblasts
- PMID: 14651778
- DOI: 10.1089/107999003322558773
Deregulated expression of interferon regulatory factor-1 in oncogene-transformed mouse fibroblasts
Abstract
Interferon (IFN) regulatory factor-1 (IRF-1) is a transcription factor that has been historically associated with type I IFN activation and antioncogenic properties. We studied IRF-1 expression and DNA-binding capacity in nontransformed and transformed mouse fibroblasts. A 43-kDa nuclear IRF-1 protein was expressed biphasically during the cell cycle in primary mouse embryo fibroblasts, nontransformed NIH 3T3 cells, and ras revertants. IRF-1 expression became constitutive in ras-transformed NIH 3T3 cells and in cells transformed by oncogenes ets, fes, fos, her-2/neu, met, mos, raf, or trk, suggesting that deregulated IRF-1 expression may be associated with loss of growth control. Lysyl oxidase (LO), a ras suppressor that is downregulated in ras transformants, is an IRF-1 target gene, but it is not stimulated by abundant IRF-1 present in transformants, while another IRF-1 target gene (iNOS) is transcribed. IRF-1 from either normal or ras-transformed cells bound to IRF elements in the IFN-beta and LO promoters. IRF-1 in transformants can, therefore, bind to but not transactivate the LO promoter, and the presence of IRF-1 is not sufficient to suppress ras transformation. LO expression may effect the regulated expression of IRF-1: a ras revertant, which was generated by stable transfection of LO cDNA, regained the normal biphasic IRF-1 pattern. A mainly cytoplasmic, constitutively expressed 46-kDa protein with immunologic identity to the 43-kDa nuclear IRF-1 was also present in normal and transformed cells, but as it did not bind to the IRF elements, its function is unclear.
Similar articles
-
Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression.Cancer Res. 1996 May 15;56(10):2417-21. Cancer Res. 1996. PMID: 8625321
-
Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene.Mol Cell Biochem. 1999 Apr;194(1-2):79-91. doi: 10.1023/a:1006913122261. Mol Cell Biochem. 1999. PMID: 10391127
-
IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo.Oncogene. 2003 Feb 20;22(7):1045-56. doi: 10.1038/sj.onc.1206260. Oncogene. 2003. PMID: 12592391
-
Interferon regulatory factors: growth control and histone gene regulation--it's not just interferon anymore.J Mol Med (Berl). 1997 May;75(5):348-59. doi: 10.1007/s001090050120. J Mol Med (Berl). 1997. PMID: 9181476 Review.
-
IRF-1 as a negative regulator of cell proliferation.J Interferon Cytokine Res. 2002 Jan;22(1):39-47. doi: 10.1089/107999002753452647. J Interferon Cytokine Res. 2002. PMID: 11846974 Review.
Cited by
-
The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer.Int J Breast Cancer. 2011;2011:912102. doi: 10.4061/2011/912102. Epub 2011 Jul 3. Int J Breast Cancer. 2011. PMID: 22295238 Free PMC article.
-
H-ras localizes to cell nuclei and varies with the cell cycle.Genes Cancer. 2011 Feb;2(2):166-72. doi: 10.1177/1947601911405042. Genes Cancer. 2011. PMID: 21779490 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous